Skip to main content
Premium Trial:

Request an Annual Quote

Binx Health Raises $65M in Series F Financing Round

NEW YORK – Binx Health last week closed a $65 million Series F financing round, company officials confirmed. 

The round was led by Hildred Capital with participation from EQT Life Sciences, Binx CEO Jeff Luber said via email. The money will be used for commercial growth, sales support, and scaling up manufacturing of its products. 

Including the new $65 million, Boston-based Binx has raised about $250 million since its inception, Luber noted. 

The firm's Binx io point-of-care platform is cleared by the US Food and Drug Administration and uses a combination of PCR amplification and electrochemical detection. In February, the company signed a US-wide distribution deal for the platform with healthcare services firm Cardinal Health. 

Last year, the firm divested its at-home testing business and refocused its efforts on point-of-care testing for sexually transmitted infections. It currently offers a CLIA-waived combination test for chlamydia and gonorrhea.